| Ytd | -2.18% | |
| 1y | -0.24% |
| Open | Prev Close | 36.84 | Low | High | Mkt Cap | 2.13B | |||
| Vol | 11.76K | Avg Vol | 848.97K | EPS | 2.48 | P/E | 14.85 | Forward P/E | 11.04 |
| Beta | 0.94 | Short Ratio | 5.83 | Inst. Own | 103.17% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 33.48 | 200-d Avg | 32.69 | 1yr Est | 44.91 |
HRMY News
PLYMOUTH MEETING, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq:
Harmony Biosciences posts preliminary Q2 2026 Wakix revenues of about $261M, up 30% year over year,
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Harmony Biosciences Hldgs (NASDAQ:
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced preliminary, unaudited second quart
Harmony Biosciences Hldgs (NASDAQ:HRMY) affirms prelim FY2026 sales outlook from $1.000 billion-$1.0
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today anno
The mean of analysts' price targets for Harmony Biosciences (HRMY) points to a 27.4% upside in the s
Deutsche Bank analyst David Hoang maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Hold a
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is likely to report earnings for its f